Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size

 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size to Grow at a CAGR of 5.7% in the Forecast Period of 2023-2031

The ‘Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Share, Analysis, Trends, Key Players, Report and Forecast 2023-2031′ by Expert Market Research provides an extensive outlook of the global non-alcoholic steatohepatitis (NASH) treatment market, assessing the market on the basis of its segments like drug classification, diagnosis, treatment type, sales channel, treatment channel, and major regions.

The report also offers a detailed insight into the market based on patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and partnership and collaborations analysis.

The report studies the latest updates in the market, along with their impact across the market. It also analyzes the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Trends, Industry Report, Key Player, Major Segments, and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

  •  Forecast CAGR (2023-2031): 5.7%
  •  Forecast Market Size (2031): 10.3 billion

The increasing prevalence of obesity, diabetes, and metabolic syndrome is expected to drive the growth of the global non-alcoholic steatohepatitis (NASH) treatment market. The development of new drugs targeting NASH by leading pharmaceutical companies is expected to provide lucrative growth opportunities for the market. However, the lack of diagnostic tools for early-stage NASH detection may pose a challenge for the market. Over the forecast period, the anticipated increase in research and development of various drugs to treat non-alcoholic steatohepatitis is expected to drive market growth. These developments, coupled with the growing demand for innovative therapies and improvements in healthcare infrastructure, are likely to contribute to market growth.

Get a Free Sample Report with Table of Contents-

Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Definition and Major Segments

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, hepatocyte injury, and liver fibrosis. It is associated with obesity, type 2 diabetes, and dyslipidaemia. Treatment options include lifestyle changes, pharmacological interventions, and liver transplantation in severe cases.

Read Full Report with Table of Contents-

Based on drug classification, the market is segmented into:

  •  Insulin Sensitizer
  •  Farnesoid X receptor Agonists
  •  Phenylimidazoles
  •  Vitamin E and Pioglitazone
  •  Others

Based on diagnosis, the market is classified into:

  •  Blood Tests
  •  CT Scan
  •  MRI Scan
  •  Abdominal Ultrasound
  •  Liver Biopsy
  •  Others

Based on distribution channel, the market is bifurcated into:

  •  Hospital Pharmacies
  •  Retail Pharmacies
  •  Online Pharmacies

Based on distribution channel, the market is bifurcated into:

  •  Public
  •  Private

Based on region, the market is segregated into:

  •  North America
  •  Europe
  •  Asia Pacific
  •  Latin America
  •  Middle East and Africa

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends

The key trends in the global non-alcoholic steatohepatitis (NASH) treatment market include increased research and development in the healthcare sector, focusing on the development of novel drug combinations and targeted therapies to combat NASH. The rise in partnerships and collaborations among pharmaceutical companies is expected to contribute to the market growth.

As the prevalence of obesity, diabetes, and metabolic syndrome increases, the demand for effective NASH treatment is expected to rise. The development of non-invasive diagnostic tools for early-stage NASH detection will likely further fuel market growth. Additionally, advancements in liver transplantation techniques and the increasing number of clinical trials for NASH treatments are projected to support market expansion.

Key Market Players

The major players in the non-alcoholic steatohepatitis (nash) treatment market report are:

  •  Gilead Sciences, Inc.
  •  Intercept Pharmaceuticals, Inc.
  •  Novo Nordisk A/S
  •  Genfit SA
  •  Allergan plc
  •  Galmed Pharmaceuticals Ltd.
  •  Others

About Us:

Expert Market Research (EMR) is a leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customizes syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work diligently to ensure that clients get only the most updated, relevant, accurate, and actionable industry intelligence so that they may formulate informed, effective, and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation
Contact Person: Jhon Roy, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA

Leave a Reply

Your email address will not be published. Required fields are marked *